Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US$1 million
How Rakovina Therapeutics designed a novel, brain-penetrant ATR inhibitor with Enki™: one design cycle to four IP-clear lead series, five optimization cycles to sub-nanomolar potency, 122 compounds, about two years,… Read More about Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US class=”wp-block-post-excerpt__more-link” href=”https://variational.ai/news/use-case/case-study-brain-penetrant-atr-inhibitor-kt-5000/” million
SK Life Science Labs Selects Variational AI’s Enki™ Platform for Generative AI-Driven Lead Discovery
Variational AI has entered a research collaboration with SK Life Science Labs, the U.S. discovery research subsidiary of SK Biopharmaceuticals. Variational AI will use its Enki™ generative AI platform to… Read More about SK Life Science Labs Selects Variational AI’s Enki™ Platform for Generative AI-Driven Lead Discovery
Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Variational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel… Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery